Revenue Search: Inside Bittensor Subnet Session with Michaela Bazo, CEO of Metanova: Rewiring Drug Discovery with SN68
12 snips
Jul 15, 2025 Michaela Bazo, CEO of Metanova, is at the forefront of revolutionizing drug discovery with the first decentralized screening platform on Bittensor. She discusses how Metanova leverages an AI-driven network to screen millions of molecules more efficiently and affordably. The conversation dives into targeting behavioral drugs, the impact of decentralization on R&D, and potential big pharma partnerships. Michaela also reveals plans for wet lab validation and the transition to a token-based revenue model, highlighting a promising future for biotech innovation.
AI Snips
Chapters
Transcript
Episode notes
Decentralized Screening Rewires Discovery
- Metanova is a decentralized drug screening platform that uses BitTensor to shortlist promising molecules against protein targets.
- Decentralization enables large-scale, computationally intensive screening and novel entry-point discovery.
AI Unlocks Novel Entry Points
- AI lets you explore entirely new molecular entry points rather than iterating minor tweaks on existing drugs.
- Novelty increases chances of patentability and addressing conditions lacking standard treatments.
Beyond Activity: Multivariate Filters
- Multiple properties matter beyond activity, like blood-brain barrier crossing, which demands multi-parameter prediction.
- Focusing only on activity ignores critical downstream failure modes that increase pipeline attrition.